Sierra Oncology (SRRA) - Progress with ongoing trials and future plans

11:28 EDT 16 Apr 2018 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Sierra Oncology: Sierra Oncology held an investor meeting on 27 February 2018, which provided a comprehensive update on its programs. The most immediately impactful data was a favourable safety profile reported from the ongoing Phase I/II clinical trials (monotherapy and gemcitabine combination). It was announced that the monotherapy trial had entered the Phase II dose-expansion portion of the trial and that the combination study will enter this phase in Q218. Preliminary results for this trial are expected in Q418.
ISIN: US82640U1079

Original Article: Sierra Oncology (SRRA) - Progress with ongoing trials and future plans


More From BioPortfolio on "Sierra Oncology (SRRA) - Progress with ongoing trials and future plans"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...